Trial reportFrontiers in immunology2022
Anakinra Pilot - a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants.
Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05280340 (Advancing IL-1Ra to Prevent Inflammatory Disease in Preterm Infants - Pilot), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Advancing IL-1Ra to Prevent Inflammatory Disease in Preterm Infants - Pilot
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Clinical Pharmacokinetics and Pharmacodynamics of the IL-1 Receptor Antagonist Anakinra: A Systematic Review.Clinical pharmacokinetics · 2026Pooled it
- Model-Informed Dose Optimization of Anakinra in Preterm Neonates Implications for Safe and Effective Dosing.Clinical pharmacology and therapeutics · 2026Article
- Bronchopulmonary dysplasia and prematurity-associated lung disease: emerging therapies to improve lifelong respiratory outcomes.European journal of pediatrics · 2026Review
- Challenges in biomarker discovery research.Pediatric research · 2026Article
- Priming innate immunity and long-term outcome.Molecular and cellular pediatrics · 2026Review
- Anakinra in a Preterm Infant with Bronchopulmonary Dysplasia: A Case Report.Children (Basel, Switzerland) · 2026Article
- Predictive value of increased C-reactive protein levels in preterm infants on respiratory function at five to six years of age.Communications medicine · 2026Article
- Dynamic association between plasma interleukin-1 family concentrations and bronchopulmonary dysplasia in extremely premature infants.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Respiratory effects of off label anakinra in critically ill neonates: a 15-patient observational cohort study.Frontiers in pediatrics · 2026Article
- Inflammatory mechanisms contribute to long-term cognitive deficits induced by perinatal asphyxia via interleukin-1.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review.Pediatric rheumatology online journal · 2025Article
- Establishment of a neonatal rat model of sequential hyperoxic hypoxia to recapitulate clinical progression of bronchopulmonary dysplasia-associated pulmonary hypertension.Intensive care medicine experimental · 2025Article
- Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).Pediatric research · 2025Article
- Inflammasome-Mediated Neuroinflammation: A Key Driver in Alzheimer's Disease Pathogenesis.Biomolecules · 2025Review
- Off-Label Use of Anakinra in Inflammatory Conditions in Neonates and Infants Up to 3 Months of Age: A Case Series and a Review of the Literature.Paediatric drugs · 2025Review
- Interleukin-1 Receptor Antagonists Partially Inhibited Histological Injury but Not Tissue Inflammation in a Sheep Model of Pregnancy.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Early immune modulation in cerebral palsy medical management of cerebral palsy series.Pediatric research · 2025Article
- Mitochondria as the central regulator of cell death in bronchopulmonary dysplasia.Frontiers in physiology · 2025Review
- Can or should we try to predict preterm white matter injury?Pediatric research · 2025Article
- Longitudinal transcriptomic analysis of the hyperoxia-exposed preterm rabbit as a model of BPD.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely. There is extensive evidence that the pro-inflammatory cytokine interleukin 1 (IL-1) plays a key role in the pathophysiology of these illnesses. Two decades of clinical use in paediatric and adult medicine have established an excellent safety and efficacy record for IL-1 blockade with IL-1 receptor antagonist (IL-1Ra, medication name anakinra). Building on robust pre-clinical evidence, the Anakinra Pilot trial aims to demonstrate safety and feasibility of administering anakinra to preterm infants, and to establish pharmacokinetics in this population. Its ultimate goal is to facilitate large studies that will test whether anakinra can ameliorate early-life inflammation, thus alleviating multiple complications of prematurity. Methods and analysis: Anakinra Pilot is an investigator-initiated, single arm, safety and feasibility dose-escalation trial in extremely preterm infants born between 24 weeks 0 days (24 Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT05280340.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.